UAE MOHAP Pharmaceutical Import & Registration Guide

MOHAP & Dubai Health Authority: Who Regulates What?

Understanding the regulatory landscape in the UAE requires navigating multiple authorities. Here's the breakdown.

Ministry of Health and Prevention (MOHAP):

MOHAP is the federal regulatory authority responsible for pharmaceutical registration, import controls, and market surveillance across all seven emirates, including Abu Dhabi, Sharjah, Ajman, Umm Al-Quwain, Ras Al-Khaimah, and Fujairah. It also has jurisdiction in Dubai for certain activities (see below).

MOHAP's core functions:

• Product registration and marketing authorization
• Inspecting manufacturing facilities (GMP audits)
• Issuing import and export permits
• Pharmacovigilance and post-market surveillance
• Clinical trial authorization
• Pricing regulation (maximum selling price)

Dubai Health Authority (DHA):

The DHA has a parallel regulatory role specific to the Emirate of Dubai. For pharmaceutical products, DHA handles:

• Registration of products sold exclusively within Dubai (though most manufacturers register with MOHAP for nationwide access)
• Licensing of healthcare facilities and pharmacies in Dubai
• Dubai-specific import permits

Critical note: Most international manufacturers register with MOHAP (federal) to access the entire UAE market. DHA registration is typically only for Dubai-specific products or as an additional registration for local distribution. Focus on MOHAP for market entry.

Free Zone Authorities:

Dubai has several free zones (JAFZA, DAFZA, Dubai Science Park) with their own licensing requirements for warehousing and distribution, but product registration still falls under MOHAP/DHA.

Registration Pathways & Product Categories

MOHAP offers multiple registration pathways aligned with international standards.

Pathway 1: Full Registration (New Chemical Entities / NCEs)

Full clinical trial data required. Timeline: 12-18 months. Cost: AED 30,000-80,000 ($8,000-22,000) in official fees.

Pathway 2: Abridged Registration (Generic Products)

The most common pathway. Requires bioequivalence data. Timeline: 8-12 months. Cost: AED 20,000-40,000 ($5,500-11,000).

Pathway 3: SRA Mutual Recognition (Fast-Track)

Products approved by US FDA, EMA, Health Canada, TGA, PMDA, MHRA, or Swissmedic qualify for accelerated review. Timeline: 4-6 months. Highly recommended.

Pathway 4: WHO Prequalification Recognition

Products with WHO PQ receive priority review. Timeline: 5-7 months.

Pathway 5: GCC Common Registration File (CRF)

One dossier reviewed by GCC committee leads to registration in UAE plus other GCC states. Timeline: 10-14 months for GCC review plus national steps.

Pathway 6: Biologics & Biosimilars

Specialized pathway. Timeline: 12-18 months. Cost: AED 50,000-100,000 ($13,600-27,200).

Prerequisites: What You Need Before Applying

Before submitting to MOHAP, ensure these items are in place.

• Appoint a Local Distributor/Agent: Foreign manufacturers cannot hold a MOHAP registration. You need a UAE company with a valid MOHAP pharmaceutical license to be your local distributor. Unlike Saudi Arabia, there is no "Scientific Office" mandate—a standard distributor agreement is sufficient.
• Execute a Power of Attorney (PoA): A notarized document authorizing your local distributor to act on your behalf. Must be apostilled and translated into Arabic.
• Obtain a Certificate of Pharmaceutical Product (CPP): Issued by the regulatory authority in your manufacturing country. Must be in WHO format, less than 2 years old, properly legalized, and translated into Arabic.
• Prepare Your eCTD Dossier: MOHAP accepts both eCTD and PDF dossiers (unlike Saudi Arabia's strict eCTD requirement). PDF is acceptable for most products.
• Product Samples: MOHAP typically requires samples for laboratory testing.

Step-by-Step Registration Process

Here's the actual process for registering with MOHAP. It's more straightforward than Saudi Arabia.

Step 1: Appoint a Local Distributor

Sign a distribution agreement with a UAE-licensed pharmaceutical distributor. Verify their MOHAP license and cold chain capabilities.

Step 2: Execute and Legalize Power of Attorney

Draft the PoA, have it notarized, apostilled, translated into Arabic, and legalized at the UAE embassy. This takes 3-4 weeks.

Step 3: Prepare Your Dossier

MOHAP accepts PDF dossiers (not strict eCTD). Format as CTD (Modules 1-5). Arabic translations required for administrative documents.

Step 4: Online Submission via MOHAP's "Pharma" System

Your distributor logs into MOHAP's electronic registration system, uploads the dossier, and pays the application fee.

Step 5: Administrative Screening (3-5 weeks)

MOHAP checks for completeness, document legalization, and Arabic translations. Deficiency letters add 3-5 weeks per cycle.

Step 6: Scientific Evaluation (4-8 months)

MOHAP evaluators review your dossier. Queries are issued via the system. You have 60-90 days to respond. Well-prepared dossiers have 1-2 query cycles.

Step 7: GMP Inspection (If Required)

MOHAP accepts WHO PQ, SRA inspections, or their own inspection. Less frequent than Saudi Arabia.

Step 8: Laboratory Testing (1-2 months)

MOHAP's labs in Abu Dhabi or Dubai test product samples. Failure leads to rejection.

Step 9: Pricing Approval (1-2 months)

MOHAP sets the Maximum Selling Price (MSP) for your product. See pricing section below.

Step 10: MOHAP Drug Registration Committee Approval (3-5 weeks)

Final approval and certificate issuance.

Dossier Requirements: The UAE eCTD Format

MOHAP accepts both eCTD and standard PDF CTD format. PDF is acceptable for most products. Here's the breakdown.

Module 1: Administrative Information (UAE-Specific)

• Application letter on manufacturer letterhead (English and Arabic)
• Cover letter from UAE distributor (Arabic)
• Power of Attorney (notarized, apostilled, Arabic translation)
• Certificate of Pharmaceutical Product (WHO format, legalized, Arabic translation, less than 2 years old)
• GMP Certificate (legalized, Arabic translation)
• Free Sale Certificate
• Manufacturing license
• Labeling and package insert (Arabic and English, Arabic legally binding)
• Patent declaration
• Distributor's MOHAP license copy

Module 2: Summaries

• Quality Overall Summary (QOS)
• Nonclinical Overview & Summary (for NCEs)
• Clinical Overview & Summary (or Bioequivalence summary)

Module 3: Quality

• Drug substance and drug product documentation
• Stability data: GCC Zone IV. Minimum 6 months accelerated, 12 months long-term at submission.

Module 4: Nonclinical Reports (NCEs Only)

Module 5: Clinical Reports

• For Generics: Bioequivalence study report against reference product registered in UAE

Local Agent Requirements: The Local Distributor

Unlike Saudi Arabia's Scientific Office mandate, the UAE has a straightforward local distributor requirement.

What Your UAE Distributor Must Have:

• Valid MOHAP pharmaceutical trading license
• Physical warehouse with appropriate storage (including cold chain if needed)
• Qualified pharmacist on staff
• Quality assurance system
• Distribution network across UAE (or specific emirates)

Distribution Agreement Considerations:

• Exclusive vs. non-exclusive: Most agreements are exclusive for a specific territory or product line.
• Term: Typically 3-5 years, renewable.
• Registration ownership: The distributor holds the registration, but you can negotiate ownership or transfer rights.
• Commission/Margin: Distributors typically take 15-25% margin.

Choosing Your Distributor:

The UAE has dozens of pharmaceutical distributors, from multinational giants to specialized local players. Key considerations:

• Do they have MOHAP registration for similar products?
• Do they have cold chain capabilities? (Essential for biologics, vaccines, insulin)
• Do they have a sales force targeting your customer segments (hospitals, retail pharmacies, government tenders)?
• What is their track record with other international manufacturers?

GMP Compliance & Facility Inspections

MOHAP's GMP requirements are aligned with WHO GMP standards.

GMP Evidence MOHAP Accepts:

• WHO Prequalification (highest acceptance)
• SRA inspection (US FDA, EMA, etc.) within last 3 years
• PIC/S member authority certificate
• MOHAP-conducted inspection

When Does MOHAP Conduct Its Own Inspection?

• First-time registration from your facility
• No recognized inspection in last 3 years
• Sterile products or high-risk products
• Previous compliance issues

Inspection Process:

1. MOHAP notifies your distributor (6-8 weeks notice)
2. Fee: AED 30,000-60,000 ($8,200-16,300) plus travel
3. Inspectors visit for 3-5 days
4. Report with findings issued
5. CAPA plan required within 30-60 days

Pricing Regulations: The Maximum Selling Price

The UAE has mandatory price controls similar to Saudi Arabia but somewhat less stringent.

How the Pricing Process Works:

1. After scientific approval, your distributor submits a pricing application to MOHAP.
2. You justify your proposed Maximum Selling Price (MSP) based on:
   • International reference pricing (prices in reference countries including Saudi Arabia, Kuwait, Qatar, Bahrain, Oman)
   • GCC reference pricing
   • Therapeutic reference pricing (similar products in UAE)
   • Manufacturing cost (limited weight)
3. MOHAP approves, rejects, or adjusts the MSP.
4. Approved MSP published in MOHAP pricing bulletin.

Key Pricing Rules:

• Generics must be priced 25-30% below originator
• Annual price increases limited to 3-5% (with justification)
• Violations result in fines (AED 50,000-500,000/$13,600-136,000)

Pricing Timeline:

• Standard: 1-2 months
• Priority: 2-4 weeks

Costs, Timelines & Budget Planning

The UAE is significantly more affordable than Saudi Arabia. Here's the financial picture.

Official MOHAP Fees (Approximate)

• Application fee: AED 5,000-10,000 ($1,400-2,700)
• Evaluation fee (generic): AED 15,000-30,000 ($4,100-8,200)
• Evaluation fee (NCE): AED 30,000-80,000 ($8,200-21,800)
• Registration certificate fee: AED 10,000-15,000 ($2,700-4,100)
• Annual retention fee: AED 3,000-8,000 ($800-2,200) per product
• Express service fee: AED 10,000-20,000 ($2,700-5,400)

Third-Party Costs

• Regulatory consultant fees: AED 50,000-150,000 ($13,600-40,800) per product
• Document legalization/translation: AED 10,000-25,000 ($2,700-6,800)
• GMP inspection (if required): AED 30,000-80,000 ($8,200-21,800)
• Bioequivalence study: AED 200,000-600,000 ($54,500-163,000) if new study needed
• Stability studies: AED 40,000-100,000 ($10,900-27,200)

Total Estimated Cost Per Product:

• Generic (SRA fast-track, existing BE): AED 80,000-150,000 ($21,800-40,800)
• Generic (standard, no inspection): AED 100,000-200,000 ($27,200-54,500)
• Generic (with inspection): AED 150,000-300,000 ($40,800-81,700)
• SRA Mutual Recognition: AED 60,000-120,000 ($16,300-32,700)

Timelines:

• SRA Mutual Recognition: 4-6 months
• WHO PQ Recognition: 5-7 months
• Standard generic (well-prepared): 8-12 months
• Generic (poor dossier): 12-18 months

Dubai vs. Abu Dhabi: Free Zone Considerations

While MOHAP registration provides nationwide access, where you establish your distribution operations matters.

Dubai (JAFZA, DAFZA, Dubai Science Park):

• Advantages: World-class logistics, Jebel Ali Port, Al Maktoum Airport, established pharma cluster, 100% foreign ownership, tax-free
• Disadvantages: Higher costs, potential DHA registration requirements for Dubai-only sales
• Best for: Re-export to Africa, Middle East, South Asia

Abu Dhabi (KEZAD, Abu Dhabi Ports):

• Advantages: Lower costs, growing pharma cluster, closer to MOHAP headquarters, good cold chain infrastructure
• Disadvantages: Less established than Dubai for pharma logistics
• Best for: UAE-focused distribution, government tenders

Free Zone vs. Mainland:

• Free Zone: 100% foreign ownership, tax-free, simplified setup, but cannot sell directly into UAE mainland without a mainland distributor
• Mainland: Can sell directly, but requires local sponsor (51% local ownership) or recent 100% foreign ownership for certain activities

Distribution & Warehousing: Cold Chain Requirements

The UAE's hot climate makes cold chain management critical for temperature-sensitive products.

Warehousing Requirements:

• Temperature-controlled storage (15-25°C for room temperature, 2-8°C for cold chain)
• 24/7 temperature monitoring and recording
• Backup power generators
• MOHAP-inspected and licensed facilities

Last-Mile Distribution:

• UAE has excellent logistics infrastructure with major couriers (Aramex, DHL, FedEx) offering pharmaceutical logistics
• Same-day or next-day delivery across all seven emirates
• Temperature-controlled vehicles required for cold chain products

Re-export Considerations:

• Jebel Ali Free Zone (JAFZA) is a major re-export hub for pharmaceuticals to Africa and the Middle East
• Re-exports do not require UAE product registration if the product is in transit and not sold in UAE
• However, re-export to other GCC countries requires registration in those countries

Common Pitfalls & Rejection Reasons

• Invalid or Expired CPP: Less than 2 years old, WHO format required
• Missing Arabic Translations: Module 1 documents must have certified Arabic translations
• Missing Notarization/Apostille: All foreign documents must be legalized
• Incorrect Reference Product for BE: Must use UAE-registered reference product
• Inadequate Stability Data: GCC Zone IV required
• No Local Distributor Agreement: Valid distributor license must be on file
• GMP Certificate Issues: Expired or not from recognized authority
• Product Sample Fails Testing: Immediate rejection
• Unreasonable Pricing Proposal: Too high compared to reference countries

Post-Registration Obligations & Renewal

• Annual Retention Fees: Payable each year, late fees apply
• Variations: Changes require MOHAP notification; major changes need approval
• Renewal: Every 5 years, start 6-9 months before expiry
• Pharmacovigilance: Your distributor must report adverse events; PSURs every 2 years
• Price Maintenance: Annual price reports required; increases limited
• Post-Market Surveillance: MOHAP samples products from pharmacies; failures lead to recalls

GCC Common Registration File: Regional Expansion

The GCC Common Registration File is your pathway to the entire GCC region from your UAE base.

Using UAE as GCC CRF Entry Point:

1. Submit dossier to GCC Executive Board (based in Riyadh, but can be submitted through UAE MOHAP)
2. Joint GCC evaluation (8-12 months)
3. GCC approval leads to national registrations in UAE, Saudi Arabia, Kuwait, Qatar, Bahrain, Oman
4. UAE MOHAP typically issues national registration within 2-3 months of GCC approval

Benefits of GCC CRF:

• One dossier, six markets
• Lower total cost than individual registrations
• Faster than sequential registrations
• Harmonized requirements

Conclusion: Your UAE Market Entry Strategy

The UAE is the ideal first GCC market for pharmaceutical exporters. It offers a balanced regulatory environment, reasonable costs, excellent infrastructure, and serves as a regional hub for distribution across the Middle East and Africa.

Your UAE registration checklist:

• ✓ Find a reputable UAE distributor with MOHAP license and cold chain capabilities
• ✓ Execute and legalize Power of Attorney with Arabic translation
• ✓ Obtain valid CPP (WHO format, less than 2 years old)
• ✓ Prepare CTD dossier (PDF acceptable, not strict eCTD)
• ✓ Ensure GMP evidence is current and from recognized authority
• ✓ Budget AED 100,000-200,000 ($27,000-54,000) per product
• ✓ Plan for 8-12 months from submission to approval
• ✓ Develop pricing strategy aligned with MOHAP reference pricing
• ✓ Consider free zone establishment (JAFZA) for regional distribution hub
• ✓ Use GCC CRF if targeting multiple GCC markets
• ✓ Hire a local regulatory consultant familiar with MOHAP processes

The UAE is the gateway to the GCC and beyond. Start here, prove your product, then expand to Saudi Arabia, Kuwait, and Qatar. The UAE's business-friendly environment, world-class infrastructure, and strategic location make it the perfect launchpad for your Middle East and Africa strategy.